Cooper, Mark E.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Cited by 7,493

Mechanisms of Diabetic Complications

Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews

Advanced Glycation End Products researchChronic Kidney Disease and Diabetes

Cited by 2,890

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine

Erythropoietin and Anemia TreatmentDialysis and Renal Disease Management

Cited by 2,096

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 1,743

Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes

Forbes, J. M., Coughlan, M. T., & Cooper, M. E. (2008) · Diabetes

Chronic Kidney Disease and DiabetesAdvanced Glycation End Products research

Cited by 1,203

Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia

El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P. L., Roeder, R. G., Cooper, M. E., & Brownlee, M. (2008) · The Journal of Experimental Medicine

Nitric Oxide and Endothelin EffectsAdvanced Glycation End Products research

Cited by 1,115

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,084

The Role of Advanced Glycation End Products in Progression and Complications of Diabetes

Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism

Advanced Glycation End Products researchChronic Kidney Disease and Diabetes

Cited by 987

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes

Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 965

Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease

Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 742

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial

Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 708

Diabetes and Kidney Disease: Role of Oxidative Stress

Jha, J. C., Banal, C., Chow, B. S. M., Cooper, M. E., & Jandeleit-Dahm, K. (2016) · Antioxidants & Redox Signaling

Chronic Kidney Disease and DiabetesNitric Oxide and Endothelin Effects

Cited by 660

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes

Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 626

Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes

Soro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., Barit, D., Coughlan, M. T., Drew, B. G., Lancaster, G. I., et al. (2008) · Diabetes

Advanced Glycation End Products researchAtherosclerosis and Cardiovascular Diseases

Cited by 407

NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis

Gray, S. P., Di Marco, E., Okabe, J., Szyndralewiez, C., Heitz, F., Montezano, A. C., de Haan, J. B., Koulis, C., El-Osta, A., Andrews, K. L., et al. (2013) · Circulation

Nitric Oxide and Endothelin EffectsNeutrophil, Myeloperoxidase and Oxidative Mechanisms

Cited by 386

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function

Holtkamp, F. A., de Zeeuw, D., Thomas, M. C., Cooper, M. E., de Graeff, P. A., Hillege, H. J. L., Parving, H.-H., Brenner, B. M., Shahinfar, S., & Lambers Heerspink, H. J. (2011) · Kidney International

Chronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Cited by 364

Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial

Hirakawa, Y., Arima, H., Zoungas, S., Ninomiya, T., Cooper, M., Hamet, P., Mancia, G., Poulter, N., Harrap, S., Woodward, M., et al. (2014) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 363

Genetic Targeting or Pharmacologic Inhibition of NADPH Oxidase Nox4 Provides Renoprotection in Long-Term Diabetic Nephropathy

Jha, J. C., Gray, S. P., Barit, D., Okabe, J., El-Osta, A., Namikoshi, T., Thallas-Bonke, V., Wingler, K., Szyndralewiez, C., Heitz, F., et al. (2014) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesRenal Diseases and Glomerulopathies

Cited by 352

Role of Advanced Glycation End Products in Diabetic Nephropathy

Forbes, J. M., Cooper, M. E., Oldfield, M. D., & Thomas, M. C. (2003) · Journal of the American Society of Nephrology

Advanced Glycation End Products researchChronic Kidney Disease and Diabetes

Cited by 351

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 316

Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes

Jandeleit-Dahm, K. A., Tikellis, C., Reid, C. M., Johnston, C. I., & Cooper, M. E. (2005) · Journal of Hypertension

Renin-Angiotensin System StudiesBlood Pressure and Hypertension Studies

Cited by 293

UKPDS and the legacy effect

Chalmers, J., & Cooper, M. E. (2008) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 263

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

Cherney, D. Z. I., Cooper, M. E., Tikkanen, I., Pfarr, E., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Lund, S. S. (2018) · Kidney International

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 243

Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON

Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., et al. (2016) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 240